Japan M&A: Prescription for growth

The cross-border acquisitions that JapanÆs pharmaceutical companies are announcing could be just what the doctor ordered, even though they come with hefty price tags.

Japanese pharmaceutical companies some of the most sophisticated and cash-rich in the world are shopping abroad for targets to enrich their drug pipelines and counter the uncertain outlook for sales in Japan. But sellers are still insisting on hefty price-tags, despite slowing economic growth and depressed equity markets.

On the face of it, Japan’s greying population looks like good news for the country's pharma businesses. More than one-fifth of Japanese people are over 65 and,...

To continue reading, please login or register for free

Print Edition

FinanceAsia Print Edition

CONFERENCES